Dec 9, 2024 12:02pm EST Rigel Highlights Initial Data from Ongoing Phase 1b Study Evaluating R289 in LR-MDS at the 66th ASH Annual Meeting and Exposition
Dec 2, 2024 8:05am EST Rigel Announces R289 Granted Fast Track Designation by the FDA for Lower-Risk MDS